Literature DB >> 9665944

T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis.

L I Sakkas1, C Scanzello, N Johanson, J Burkholder, A Mitra, P Salgame, C D Katsetos, C D Platsoucas.   

Abstract

The synovial membrane in osteoarthritis (OA) often exhibits inflammatory infiltrates, but the role of T cells in these infiltrates is not known. T-cell activation antigens were analyzed by immunohistochemistry, and T-cell cytokine transcripts were measured by competitive PCR in synovial membranes from patients with OA and rheumatoid arthritis (RA). Lymphoid cell aggregates, containing primarily CD3+ T lymphocytes, were found in 65% of patients with OA. Mononuclear cells expressing the activation antigens CD69, CD25, CD38, CD43, CD45RO, and HLA class II were present in both patient groups, although in higher numbers in patients with RA. Interleukin 2 (IL-2) transcripts were found in 10 of 18 patients with OA versus 12 of 13 patients with RA (P = 0.03). Gamma interferon (IFN-gamma) transcripts were detected in 9 of 18 patients with OA versus 10 of 13 patients with RA (not significant), whereas IL-10 transcripts were found in nearly all patients. IL-4 and IL-5 were not detected in any patients. The levels of IFN-gamma and IL-2 transcripts, normalized for T-cell number equivalents, were not statistically different between OA and RA, but the levels of IFN-gamma, normalized for total cell number equivalents, were lower in OA than in RA (P = 0.01). Synovial membranes that expressed IL-2 and IFN-gamma transcripts were more likely to have heavier infiltrations of T cells and cells bearing activation markers than synovial membranes that did not express these cytokines. The presence of activated T cells and TH1 cytokine transcripts in chronic joint lesions of patients with OA suggests that T cells contribute to chronic inflammation in a large proportion of these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665944      PMCID: PMC95595          DOI: 10.1128/CDLI.5.4.430-437.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  56 in total

1.  Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.

Authors:  S A Fulton; J M Johnsen; S F Wolf; D S Sieburth; W H Boom
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction.

Authors:  L A Joosten; E Lubberts; P Durez; M M Helsen; M J Jacobs; M Goldman; W B van den Berg
Journal:  Arthritis Rheum       Date:  1997-02

3.  Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis.

Authors:  R J Dolhain; N T ter Haar; S Hoefakker; P P Tak; M de Ley; E Claassen; F C Breedveld; A M Miltenburg
Journal:  Br J Rheumatol       Date:  1996-01

4.  IL-12 induces human T cells secreting IL-10 with IFN-gamma.

Authors:  A Windhagen; D E Anderson; A Carrizosa; R E Williams; D A Hafler
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

Review 5.  Acute-phase proteins in osteoarthritis.

Authors:  J D Sipe
Journal:  Semin Arthritis Rheum       Date:  1995-10       Impact factor: 5.532

6.  Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells.

Authors:  E Sugiyama; A Kuroda; H Taki; M Ikemoto; T Hori; N Yamashita; M Maruyama; M Kobayashi
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

7.  Macrophage inflammatory protein-1 beta: a C-C chemokine in osteoarthritis.

Authors:  A E Koch; S L Kunkel; M R Shah; R Fu; D D Mazarakis; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  Clin Immunol Immunopathol       Date:  1995-12

8.  Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA).

Authors:  A Bucht; P Larsson; L Weisbrot; C Thorne; P Pisa; G Smedegård; E C Keystone; A Grönberg
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

9.  Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies.

Authors:  J F Schlaak; I Pfers; K H Meyer Zum Büschenfelde; E Märker-Hermann
Journal:  Clin Exp Rheumatol       Date:  1996 Mar-Apr       Impact factor: 4.473

10.  Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10.

Authors:  F Gerosa; C Paganin; D Peritt; F Paiola; M T Scupoli; M Aste-Amezaga; I Frank; G Trinchieri
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  44 in total

Review 1.  The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.

Authors:  Jérémie Sellam; Francis Berenbaum
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Enhanced production of MMP-1, MMP-3, MMP-13, and RANTES by interaction of chondrocytes with autologous T cells.

Authors:  Hiroshi Nakamura; Michiaki Tanaka; Kayo Masuko-Hongo; Kazuo Yudoh; Tomohiro Kato; Moroe Beppu; Kusuki Nishioka
Journal:  Rheumatol Int       Date:  2006-02-09       Impact factor: 2.631

Review 3.  Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.

Authors:  Niamh Fahy; Eric Farrell; Thomas Ritter; Aideen E Ryan; J Mary Murphy
Journal:  Tissue Eng Part B Rev       Date:  2014-08-04       Impact factor: 6.389

Review 4.  Cellular immunity in osteoarthritis: novel concepts for an old disease.

Authors:  S N Liossis; G C Tsokos
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

5.  Biophysical stimulation improves clinical results of matrix-assisted autologous chondrocyte implantation in the treatment of chondral lesions of the knee.

Authors:  Marco Collarile; Andrea Sambri; Giada Lullini; Matteo Cadossi; Claudio Zorzi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-06-17       Impact factor: 4.342

Review 6.  Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.

Authors:  John L Hamilton; Masashi Nagao; Brett R Levine; Di Chen; Bjorn R Olsen; Hee-Jeong Im
Journal:  J Bone Miner Res       Date:  2016-04-08       Impact factor: 6.741

Review 7.  Interleukin-7 induced immunopathology in arthritis.

Authors:  S A Y Hartgring; J W J Bijlsma; F P J G Lafeber; J A G van Roon
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

8.  Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls.

Authors:  R Rollín; F Marco; J A Jover; J A García-Asenjo; L Rodríguez; L López-Durán; B Fernández-Gutiérrez
Journal:  Rheumatol Int       Date:  2008-01-18       Impact factor: 2.631

9.  The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes.

Authors:  Hui Du; Kayo Masuko-Hongo; Hiroshi Nakamura; Yang Xiang; Chun-De Bao; Xiao-Dong Wang; Shun-Le Chen; Kusuki Nishioka; Tomohiro Kato
Journal:  Rheumatol Int       Date:  2004-09-18       Impact factor: 2.631

10.  Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes.

Authors:  Carina Strell; Anne Sievers; Philipp Bastian; Kerstin Lang; Bernd Niggemann; Kurt S Zänker; Frank Entschladen
Journal:  BMC Immunol       Date:  2009-12-08       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.